<DOC>
	<DOC>NCT02481180</DOC>
	<brief_summary>The purpose of this study is to assess the MTD, Pharmacokinetics and preliminary efficacy of T0001 in Rheumatoid Arthritis.</brief_summary>
	<brief_title>Tolerance, Pharmacokinetics and Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Age 1845 years old; Diagnosed with active RA; DMARDs therapy must not be used for at least 28 days prior to baseline; If a patient has received NSAIDs，current NSAIDs therapy must have been at a stable dose for at least 28 days prior to baseline; Patient or patient's legal representative able to give written informed consent for participation in the trial. Acute or chronic infection, or history of active tuberculosis; History of diseases of central nervous system, cardiovascular system, kidney, liver ( specified liver function index), digestive system, respiratory system , metabolism system; Patients who have a high risk of infection (with a current infectious disease, a chronic infectious disease, a history of serious infectious disease); Patients who use 5 Unit doses tuberculin skin test are positive( 4872 hour scleroma reading≥5mm); Patients who currently have, or who have a history of, malignancy; Patients who lack of understanding ,communication or collaboration, and can't comply with the protocols; Female patients who are breastfeeding or pregnant, who are of childbearing potential.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>